Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Stanford researchers have defined subgroups of regulatory T cell (Tregs), CD39+ and CD39-, that can be genetically engineered to produce enhanced or reduced cytotoxicity without affecting their ability to suppress the immune system.
Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.
Stanford inventors have developed technologies for improved islet transplantation using a bioscaffold platform that maintains islet health during and after their transplantation.
Stanford inventors have developed technologies for improved islet transplantation using a bioscaffold platform that maintains islet health during and after their transplantation.